Cite
HARVARD Citation
Yang, Y. et al. (2021). Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial. Lancet oncology. 22 (8), pp. 1162-1174. [Online].